blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3389664

EP3389664 - CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  10.12.2021
Database last updated on 07.10.2024
FormerRequest for examination was made
Status updated on  21.09.2018
FormerThe international publication has been made
Status updated on  23.06.2017
Most recent event   Tooltip27.12.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Raze Therapeutics, Inc.
400 Technology Square
10th Floor
Cambridge, Massachusetts 02139 / US
[N/P]
Former [2018/43]For all designated states
Raze Therapeutics Inc.
400 Technology Square
10th Floor
Cambridge, Massachusetts 02139 / US
Inventor(s)01 / MAINOLFI, Nello
12 Oakley Raod
Belmont, MA 02478 / US
02 / MOYER, Mikel, P.
21 Atherton Road
Brookline, MA 02446 / US
03 / SAIAH, Eddine
19 Kenwood Street
Brookline, MA 02446 / US
04 / LECCI, Cristina
114 Innovation Drive
Milton Park;
Abingdon Oxfordshire OX14 4RZ / GB
05 / PACE, Robert, David, Matthew
114 Innovation Drive
Milton Park;
Abingdon Oxfordshire OX14 4RZ / GB
06 / TYE, Heather
114 Innovation Drive
Milton Park;
Abingdon Oxfordshire OX14 4RZ / GB
07 / VILE, Julia
114 Innovation Drive
Milton Park;
Abingdon Oxfordshire OX14 4RZ / GB
 [2018/43]
Representative(s)Tostmann, Holger Carl
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstrasse 5-7
80331 München / DE
[2018/43]
Application number, filing date16876595.614.12.2016
[2018/43]
WO2016US66666
Priority number, dateUS201562266802P14.12.2015         Original published format: US 201562266802 P
[2018/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017106352
Date:22.06.2017
Language:EN
[2017/25]
Type: A1 Application with search report 
No.:EP3389664
Date:24.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 22.06.2017 takes the place of the publication of the European patent application.
[2018/43]
Search report(s)International search report - published on:US22.06.2017
(Supplementary) European search report - dispatched on:EP09.12.2019
ClassificationIPC:A61K31/522, A61P35/02, A61P35/04
[2018/43]
CPC:
C07D473/30 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP,US);
C07D473/18 (EP,US); A61P17/06 (EP,US); A61P19/02 (EP,US);
A61P3/04 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/43]
TitleGerman:KOFFEININHIBITOREN VON MTHFD2 UND VERWENDUNGEN DAFÜR[2018/43]
English:CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF[2018/43]
French:INHIBITEURS DE CAFÉINE DE MTHFD2 ET LEURS UTILISATIONS[2018/43]
Entry into regional phase13.06.2018National basic fee paid 
13.06.2018Search fee paid 
13.06.2018Designation fee(s) paid 
13.06.2018Examination fee paid 
Examination procedure13.06.2018Examination requested  [2018/43]
13.06.2018Date on which the examining division has become responsible
20.07.2020Amendment by applicant (claims and/or description)
13.12.2021Despatch of a communication from the examining division (Time limit: M04)
12.04.2022Reply to a communication from the examining division
29.07.2022Despatch of a communication from the examining division (Time limit: M06)
20.01.2023Reply to a communication from the examining division
16.03.2023Despatch of a communication from the examining division (Time limit: M04)
12.07.2023Reply to a communication from the examining division
28.07.2023Despatch of a communication from the examining division (Time limit: M04)
06.11.2023Reply to a communication from the examining division
Fees paidRenewal fee
31.12.2018Renewal fee patent year 03
27.12.2019Renewal fee patent year 04
28.12.2020Renewal fee patent year 05
27.12.2021Renewal fee patent year 06
27.12.2022Renewal fee patent year 07
27.12.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US3094529  ;
 [X]DE1938016  (FISCHER OHG ARZNEIMITTELWERK);
 [X]US6020337  (LEIGH ALISTAIR J [US], et al);
 [X]WO0116134  (UNIV VANDERBILT [US]);
 [X]WO2004106337  (CV THERAPEUTICS INC [US]);
 [X]WO2005021548  (ADENOSINE THERAPEUTICS LLC [US], et al);
 [X]WO2006091897  (ADENOSINE THERAPEUTICS LLC [US], et al);
 [X]US7253176  (WAER MARK JOZEF ALBERT [BE], et al);
 [X]US2007197563  (SCHOENAFINGER KARL [DE], et al);
 [X]WO2009024542  (BOEHRINGER INGELHEIM INT [DE], et al);
 [X]WO2011005871  (PGXHEALTH LLC [US], et al);
 [X]CN102993203  (WENZHOU MEDICAL COLLEGE)
International search[X]US2009023704  (CHENG LEIFENG [SE], et al) [X] 1-3, 5-8, 18-19 * ; abstract; paragraphs [0047], [0049], [0055], [0046], [0061], [0670]-[0671], [0737], [0754] * [] 9-16, 20/1-3, 20/5-16, 21/1-3, 21/5-16, 22/1-3, 22/5-16, 23/22/1-3, 23/22/5-16, 24/23/22/1-3, 24/23/22/5-16, 25/23/22/1-3, 25/23/22/5-16, 26/23/22/1-3, 26/23/22/5-16, 27/23/22/1-3, 27/23/22/5-16, 28/2;
 [Y]US2009105282  (PICKETT CECIL [US], et al) [Y] 9-16, 20/9-16, 21/9-16, 22/9-16, 23/22/9-16, 24/23/22/9-16, 25/23/22/9-16, 26/23/22/9-16, 27/23/22/9-16, 28/27/23/22/9-16 * ; paragraphs [0005], [0030] *;
 [A]US8029770  (LU YAOPING [US], et al) [A] 1* ; entire publication *;
 [Y]WO2014150688  (GEN HOSPITAL CORP [US]) [Y] 20/1-16, 21/1-17, 22/1-16, 23/22/1-17, 24/23/22/1-17, 25/23/22/1-17, 26/23/22/1-17, 27/23/22/1-17, 28/27/23/22/1-17 * ; abstract; page 2, lines 5-15, 25-30; page 6, lines 14-15; page 8, lines 15-20; page 9, lines 1-5; page 19, lines 25-30; page 45, lines 20-25; page 49, lines 10-25; figure 5 *;
 [X]  - FINGERT, HJ et al., "Cytotoxic, Cell Cycle, and Chromosomal Effects of Methylxanthines in Human Tumor Cells Treated with Alkylating Agents.", Cancer Research, (19860500), vol. 46, pages 2463 - 2467, XP055395143 [X] 1-4 20/4, 21/4, 22/4, 23/22/4, 24/23/22/4, 25/23/22/4, 26/23/22/4, 27/23/22/4, 28/27/23/22/4 * ; abstract; page 2463, column 1, paragraph 2; page 2463, column 2, paragraph 4; page 2467, column 1, paragraph 2 *
 [XY]  - PUBCHEM., (01181620), Database accession no. 110205319, XP055395146 [X] 1, 17 [Y] 20/17, 21/17, 22/17, 23/22/17, 24/23/22/17, 25/23/22/17, 26/23/22/17, 27/23/22/17, 28/27/23/22/17
 [XY]  - PUBCHEM., (20050809), Database accession no. CID 3139419, XP055395152 [X] 1 [Y] 17, 20/17, 21/17, 22/17, 23/22/17, 24/23/22/17, 25/23/22/17, 26/23/22/17, 27/23/22/17, 28/27/23/22/17
 [Y]  - DE NUNZIO, C et al., "The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation.", European urology, (20110700), vol. 60, no. 1, pages 106 - 117, XP028223808 [Y] 9-16 * ; abstract *

DOI:   http://dx.doi.org/10.1016/j.eururo.2011.03.055
 [Y]  - WEINBERG, SE et al., "Targeting mitochondria metabolism for cancer therapy.", Nature Chemical Biology, (20150100), vol. 11, no. 1, pages 9 - 15, XP055395159 [Y] 20/17, 21/17, 22/17, 23/22/17, 24/23/22/17, 25/23/22/17, 26/23/22/17, 27/23/22/17, 28/27/23/22/17 * ; page 3, paragraph 3; figure 3 *

DOI:   http://dx.doi.org/10.1038/nchembio.1712
by applicantWO00142246
 FR901228
 US5639600
 US6020337
 WO0116134
 WO02088112
 US6552065
 WO03063794
 WO2004019973
 WO2004089925
 WO2004106337
 WO2004106328
 WO2005007623
 WO2005021548
 WO2005113554
 WO2006078846
 US7087648
 WO2006091897
 WO2006122806
 WO2007016176
 WO2007044729
 WO2007053452
 WO2007070514
 WO2007084786
 US7253176
 US2007197563
 WO2007129161
 WO2008039218
 US7390799
 WO2008109943
 WO2008118802
 WO2009024542
 WO2009114512
 WO2011005871
 WO2011090760
 US8138347
 CN102993203
    - S. M. BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
    - HELLMAN et al., Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, (19930000), vol. 1, pages 248 - 275
    - The Merck Index
    - Collect. Czech. Chem. Commun., (19900000), vol. 55, pages 2257 - 2269
    - J. Med. Chem., (19960000), vol. 39, pages 2 - 9
    - J. Med. Chem., (19970000), vol. 40, pages 4396 - 4405
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.